Abstract
Non-Communicable Diseases (NCDs) are among the most pressing global health problems of the twenty-first century. Their rising incidence and prevalence is linked to severe morbidity and mortality, and they are putting economic and managerial pressure on healthcare systems around the world. Moreover, NCDs are impeding healthy aging by negatively affecting the quality of life of a growing number of the global population. NCDs result from the interaction of various genetic, environmental and habitual factors, and cluster in complex ways, making the complex identification of resulting phenotypes not only difficult, but also a top research priority. The degree of complexity required to interpret large patient datasets generated by advanced high-throughput functional genomics assays has now increased to the point that novel computational biology approaches are essential to extract information that is relevant to the clinical decision-making process. Consequently, system-level models that interpret the interactions between extensive tissues, cellular and molecular measurements and clinical features are also being created to identify new disease phenotypes, so that disease definition and treatment are optimized, and novel therapeutic targets discovered. Likewise, Systems Medicine (SM) platforms applied to extensively-characterized patients provide a basis for more targeted clinical trials, and represent a promising tool to achieve better prevention and patient care, thereby promoting healthy aging globally. The present paper: (1) reviews the novel systems approaches to NCDs; (2) discusses how to move efficiently from Systems Biology to Systems Medicine; and (3) presents the scientific and clinical background of the San Raffaele Systems Medicine Platform.
Keywords: Systems medicine, non-communicable diseases, P4 medicine, systems biology.
Current Pharmaceutical Design
Title:A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Volume: 20 Issue: 38
Author(s): Paolo Maria Rossini, Achille Lococo, Dieter Maier, Frederick Marcus, Stefano Margaritora, Camillo Marra, Gianfranco Minati, Monica Neri, Franco Pasqua, Christophe Pison, Christian Pristipino, Joseph Roca, Giuseppe Rosano, Filippo Lococo, Patrizia Russo, Gianluca Salinaro, Shani Shenhar, Hermona Soreq, Peter J. Sterk, Fabrizio Stocchi, Margherita Torti, Maurizio Volterrani, Emiel F.M. Wouters, Alessandra Frustaci, Stefano Bonassi, Nikolai Daraselia, Charles Auffray, Alvar Agusti, Giovanni Apolone, Rudi Balling, Piero Barbanti, Alfonso Bellia, Stefania Boccia, Jean Bousquet, Vittorio Cardaci, Mario Cazzola, Valentina Dall'Armi, Alfredo Cesario, Lucio Da Ros, Alessandra Del Bufalo, Giuseppe Ducci, Luigi Ferri, Massimo Fini, Chiara Fossati, Gianfranco Gensini, Pierluigi Maria Granone, James Kinross, Davide Lauro and Gerland Lo Cascio
Affiliation:
Keywords: Systems medicine, non-communicable diseases, P4 medicine, systems biology.
Abstract: Non-Communicable Diseases (NCDs) are among the most pressing global health problems of the twenty-first century. Their rising incidence and prevalence is linked to severe morbidity and mortality, and they are putting economic and managerial pressure on healthcare systems around the world. Moreover, NCDs are impeding healthy aging by negatively affecting the quality of life of a growing number of the global population. NCDs result from the interaction of various genetic, environmental and habitual factors, and cluster in complex ways, making the complex identification of resulting phenotypes not only difficult, but also a top research priority. The degree of complexity required to interpret large patient datasets generated by advanced high-throughput functional genomics assays has now increased to the point that novel computational biology approaches are essential to extract information that is relevant to the clinical decision-making process. Consequently, system-level models that interpret the interactions between extensive tissues, cellular and molecular measurements and clinical features are also being created to identify new disease phenotypes, so that disease definition and treatment are optimized, and novel therapeutic targets discovered. Likewise, Systems Medicine (SM) platforms applied to extensively-characterized patients provide a basis for more targeted clinical trials, and represent a promising tool to achieve better prevention and patient care, thereby promoting healthy aging globally. The present paper: (1) reviews the novel systems approaches to NCDs; (2) discusses how to move efficiently from Systems Biology to Systems Medicine; and (3) presents the scientific and clinical background of the San Raffaele Systems Medicine Platform.
Export Options
About this article
Cite this article as:
Rossini Maria Paolo, Lococo Achille, Maier Dieter, Marcus Frederick, Margaritora Stefano, Marra Camillo, Minati Gianfranco, Neri Monica, Pasqua Franco, Pison Christophe, Pristipino Christian, Roca Joseph, Rosano Giuseppe, Lococo Filippo, Russo Patrizia, Salinaro Gianluca, Shenhar Shani, Soreq Hermona, Sterk J. Peter, Stocchi Fabrizio, Torti Margherita, Volterrani Maurizio, Wouters F.M. Emiel, Frustaci Alessandra, Bonassi Stefano, Daraselia Nikolai, Auffray Charles, Agusti Alvar, Apolone Giovanni, Balling Rudi, Barbanti Piero, Bellia Alfonso, Boccia Stefania, Bousquet Jean, Cardaci Vittorio, Cazzola Mario, Dall'Armi Valentina, Cesario Alfredo, Ros Da Lucio, Bufalo Del Alessandra, Ducci Giuseppe, Ferri Luigi, Fini Massimo, Fossati Chiara, Gensini Gianfranco, Granone Maria Pierluigi, Kinross James, Lauro Davide and Cascio Lo Gerland, A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases, Current Pharmaceutical Design 2014; 20 (38) . https://dx.doi.org/10.2174/1381612820666140314130449
DOI https://dx.doi.org/10.2174/1381612820666140314130449 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation
Letters in Organic Chemistry Molecular Targets of Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Odontogenic Infections in the Etiology of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets A Novel Finding: Macrophages Involved in Inflammation Participate in Acute Aortic Dissection Complicated with Acute Lung Injury
Current Molecular Medicine Vulnerable Plaque Versus Vulnerable Patient: Emerging Blood Biomarkers for Risk Stratification
Endocrine, Metabolic & Immune Disorders - Drug Targets Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research A Hybrid Binary Cuckoo Search and Genetic Algorithm for Feature Selection in Type-2 Diabetes
Current Bioinformatics Inhibitors of Mammalian Acetyl-CoA Carboxylase
Recent Patents on Cardiovascular Drug Discovery Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in Treatment Approaches of Mucopolysaccharidosis VI
Current Pharmaceutical Biotechnology Epigenomic Approach in Understanding Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety